Prescription drug · ANDA
Icatibant NDC 55150-351
Icatibant acetate 30 mg/3mL · Injection, Solution · Subcutaneous · Eugia US LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 55150-351-01 | 5515003510155150035101 | 1 SYRINGE, GLASS in 1 CARTON (55150-351-01) / 3 mL in 1 SYRINGE, GLASSMarketed from Aug 14, 2023 | |
| 55150-351-03 | 5515003510355150035103 | 3 CARTON in 1 CARTON (55150-351-03) / 1 SYRINGE, GLASS in 1 CARTON / 3 mL in 1 SYRINGE, GLASSMarketed from Aug 14, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Icatibant
- Generic name (nonproprietary)
- icatibant
- Active ingredients
- Icatibant acetate — 30 mg/3mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Eugia US LLCNDC labeler code 55150
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213521
- Marketing start
- Listing expires
- Other FDA classes
- Bradykinin B2 Receptor Antagonists (Mechanism)
- Identifiers
- Product ID 55150-351_ff0f66d4-bb7c-43a6-9475-f8d87f21abb4SPL ID ff0f66d4-bb7c-43a6-9475-f8d87f21abb4SPL set ID 56d5047e-3f99-4100-af4f-388870986cedRxCUI 1148141UNII 325O8467XKUPC 0355150351015
- Pharmacologic class
- Bradykinin B2 Receptor Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N455150035101followed by a unit qualifier and the quantityPackage 55150-0351-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Icatibant injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 55150-351
- What is NDC 55150-351?
- 55150-351 is the product NDC for Icatibant, Icatibant acetate 30 mg/3mL injection, solution, listed with the FDA by Eugia US LLC. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Icatibant.
- What is the active ingredient?
- Icatibant acetate.
- Who is the labeler?
- Eugia US LLC, NDC labeler code 55150. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Icatibant?
- 6 other product NDCs are listed under this name. See all Icatibant NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Icatibant products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Icatibant | Icatibant acetate 30 mg/3mL | InjectionSubcutaneous | Alembic Pharmaceuticals Limited | 46708-654 | 46708-0654-0346708-0654-09 |
| Icatibant | Icatibant acetate 30 mg/3mL | InjectionSubcutaneous | Alembic Pharmaceuticals Inc. | 62332-654 | 62332-0654-0362332-0654-09 |
| Icatibant | Icatibant acetate 10 mg/mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 63323-574 | 63323-0574-8663323-0574-93 |
| Icatibant | Icatibant acetate 30 mg/3mL | InjectionSubcutaneous | Cipla USA Inc. | 69097-664 | 69097-0664-3469097-0664-68 |
| Icatibant | Icatibant acetate 30 mg/3mL | Injection, SolutionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 24201-207 | 24201-0207-0124201-0207-03 |
| Icatibant | Icatibant acetate 10 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 0093-3066 | 00093-3066-3400093-3066-93 |